FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 335:609-616 August 29, 1996 Number 9 Next

	Full Text PDF Letters Letters Letters Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Recently in France, primary pulmonary hypertension developed in a cluster of patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension.

Methods In a case–control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age.

Results The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used for a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs.

Conclusions The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since the use of anorexic drugs is expected to increase in the near future.

Source Information

From the Centre for Clinical Epidemiology and Community Studies, McGill University and Sir Mortimer B. Davis–Jewish General Hospital, Montreal (L.A., Y.M.); the Pneumology Service, Antoine Béclère Hospital, Clamart, France (F.B., G.S.); the Section of Cardiology, University of Illinois, Chicago (S.R.); the National Cancer Institute, Rockville, Md. (J.B.); the Pharmacology Laboratory, Pathology Institute, Centre Hospitalier Universitaire de Liège, Liege, Belgium (X.K.); the Section of Respiratory Medicine, University of Sheffield, Sheffield, United Kingdom (T.H.); the Department of Cardiology, Hammersmith Hospital, London (C.O.); the Department of Pulmonology, University Hospital Maastricht, Maastricht, the Netherlands (E.W.); the Pneumology Service, Bichat Hospital, Paris (M.A.); and the Centre for Pharmacovigilance, Pellegrin Hospital, Bordeaux, France (B.B.).

Address reprint requests to Dr. Abenhaim at the Centre for Clinical Epidemiology and Community Studies, Sir Mortimer B. Davis–Jewish General Hospital and McGill University, 3755 Côte Sainte-Catherine, Montreal, QC H3T 1E2, Canada.

Full Text of this Article

Related Letters:

Appetite-Suppressant Drugs and Primary Pulmonary Hypertension
Sobieraj J., Schembre D. B., Boynton K. K., Fishman A. P., Hoffman R. M., Upson D., Dhurandhar N. V., Atkinson R. L., Williamson D. F., Abenhaim L., Rich S., Bénichou J., Begaud B., The International Primary Pulmonary Hypertension Study Group
Extract | Full Text  
N Engl J Med 1997; 336:510-513, Feb 13, 1997. Correspondence

Valvular Heart Disease Associated with Fenfluramine–Phentermine
Thompson P. D., Kurz X., Van Ermen A., Rasmussen S., Corya B. C., Glassman R. D., Redmon B., Raatz S., Bantle J. P., Wolff F. W., Spitzer W. O., Marshall E. M., Connolly H. M., McGoon M. D., Curfman G. D.
Extract | Full Text  
N Engl J Med 1997; 337:1772-1776, Dec 11, 1997. Correspondence

Digital Necrosis Associated with Dexfenfluramine
Marinella M. A., Berrettoni B. A.
Extract | Full Text  
N Engl J Med 1997; 337:1776-1777, Dec 11, 1997. Correspondence

Appetite-Suppressant Drugs and Valvular Heart Disease
Williamson D. F., Yanovski S. Z., Myers M. D., Moye L. A., Annegers J. F., Paoletti C. F., Shapiro S., Khan M. A., St. Peter J. V., Herzog C. A., Jick H., Weissman N. J., Gottdiener J. S., Gwynne J. T., Devereux R. B., Cannistra L. B., Cannistra A. J.
Extract | Full Text  
N Engl J Med 1999; 340:476-480, Feb 11, 1999. Correspondence

Primary Pulmonary Hypertension and Anorectic Drugs
Louis W.J., Abenhaim L., Rich S., Benichou J., Begaud B.
Extract | Full Text  
N Engl J Med 1999; 340:480-482, Feb 11, 1999. Correspondence

This article has been cited by other articles:

• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full Text]  
• Sun, C.-K., Lee, F.-Y., Sheu, J.-J., Yuen, C.-M., Chua, S., Chung, S.-Y., Chai, H.-T., Chen, Y.-T., Kao, Y.-H., Chang, L.-T., Yip, H.-K. (2009). Early Combined Treatment with Cilostazol and Bone Marrow-Derived Endothelial Progenitor Cells Markedly Attenuates Pulmonary Arterial Hypertension in Rats. J. Pharmacol. Exp. Ther. 330: 718-726 [Abstract] [Full Text]  
• Shah, S. J., Gomberg-Maitland, M., Thenappan, T., Rich, S. (2009). Selective Serotonin Reuptake Inhibitors and the Incidence and Outcome of Pulmonary Hypertension. Chest 136: 694-700 [Abstract] [Full Text]  
• Roberts, K. E., Fallon, M. B., Krowka, M. J., Benza, R. L., Knowles, J. A., Badesch, D. B., Brown, R. S. Jr, Taichman, D. B., Trotter, J., Zacks, S., Horn, E. M., Kawut, S. M., for the Pulmonary Vascular Complications of Liver, (2009). Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. Chest 135: 1470-1475 [Abstract] [Full Text]  
• Lavie, C. J., Milani, R. V., Ventura, H. O. (2009). Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss.. J Am Coll Cardiol 53: 1925-1932 [Abstract] [Full Text]  
• Yu, Y., Keller, S. H., Remillard, C. V., Safrina, O., Nicholson, A., Zhang, S. L., Jiang, W., Vangala, N., Landsberg, J. W., Wang, J.-Y., Thistlethwaite, P. A., Channick, R. N., Robbins, I. M., Loyd, J. E., Ghofrani, H. A., Grimminger, F., Schermuly, R. T., Cahalan, M. D., Rubin, L. J., Yuan, J. X.-J. (2009). A Functional Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension. Circulation 119: 2313-2322 [Abstract] [Full Text]  
• McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., Rubin, L. J., Tapson, V. F., Varga, J. (2009). ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53: 1573-1619 [Full Text]  
• Writing Committee Members, , McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., Rubin, L. J., Tapson, V. F., Varga, J. (2009). ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119: 2250-2294 [Full Text]  
• Humbert, M. (2009). Update in Pulmonary Hypertension 2008. Am. J. Respir. Crit. Care Med. 179: 650-656 [Full Text]  
• Grunig, E., Weissmann, S., Ehlken, N., Fijalkowska, A., Fischer, C., Fourme, T., Galie, N., Ghofrani, A., Harrison, R. E., Huez, S., Humbert, M., Janssen, B., Kober, J., Koehler, R., Machado, R. D., Mereles, D., Naeije, R., Olschewski, H., Provencher, S., Reichenberger, F., Retailleau, K., Rocchi, G., Simonneau, G., Torbicki, A., Trembath, R., Seeger, W. (2009). Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension: Results of a Multicenter European Analysis of Pulmonary Artery Pressure Response to Exercise and Hypoxia. Circulation 119: 1747-1757 [Abstract] [Full Text]  
• Boutet, K., Frachon, I., Jobic, Y., Gut-Gobert, C., Leroyer, C., Carlhant-Kowalski, D., Sitbon, O., Simonneau, G., Humbert, M. (2009). Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 33: 684-688 [Abstract] [Full Text]  
• Zamanian, R. T., Hansmann, G., Snook, S., Lilienfeld, D., Rappaport, K. M., Reaven, G. M., Rabinovitch, M., Doyle, R. L. (2009). Insulin resistance in pulmonary arterial hypertension. Eur Respir J 33: 318-324 [Abstract] [Full Text]  
• McGoon, M. D., Kane, G. C. (2009). Pulmonary Hypertension: Diagnosis and Management. Mayo Clin Proc. 84: 191-207 [Abstract] [Full Text]  
• Watts, S. W. (2009). The love of a lifetime: 5-HT in the cardiovascular system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R252-R256 [Abstract] [Full Text]  
• Montani, D., Price, L. C., Dorfmuller, P., Achouh, L., Jais, X., Yaici, A., Sitbon, O., Musset, D., Simonneau, G., Humbert, M. (2009). Pulmonary veno-occlusive disease. Eur Respir J 33: 189-200 [Abstract] [Full Text]  
• Kamp, D. W. (2009). Drug-Induced Lung Diseases. ACCP Pulmonary Med Brd Rev 25: 319-344 [Full Text]  
• Elangbam, C. S. (2009). REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. Vet Pathol 46: 10-24 [Abstract] [Full Text]  
• Garfield, A. S., Heisler, L. K. (2009). Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 587: 49-60 [Abstract] [Full Text]  
• Ho, P. M., Peterson, P. N., Masoudi, F. A. (2008). Evaluating the Evidence: Is There a Rigid Hierarchy?. Circulation 118: 1675-1684 [Full Text]  
• 2006 WRITING COMMITTEE MEMBERS, , Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S. (2008). 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118: e523-e661 [Full Text]  
• Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S., Nishimura, R. A., Carabello, B. A., Faxon, D. P., Freed, M. D., Lytle, B. W., O'Gara, P. T., O'Rourke, R. A., Shah, P. M. (2008). 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e1-e142 [Full Text]  
• El-Bizri, N., Guignabert, C., Wang, L., Cheng, A., Stankunas, K., Chang, C.-P., Mishina, Y., Rabinovitch, M. (2008). SM22{alpha}-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. Development 135: 2981-2991 [Abstract] [Full Text]  
• Dempsie, Y., Morecroft, I., Welsh, D. J., MacRitchie, N. A., Herold, N., Loughlin, L., Nilsen, M., Peacock, A. J., Harmar, A., Bader, M., MacLean, M. R. (2008). Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation 117: 2928-2937 [Abstract] [Full Text]  
• Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., Al-Shamma, H., Smith, B., Chalmers, D., Behan, D. (2008). Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization. J. Pharmacol. Exp. Ther. 325: 577-587 [Abstract] [Full Text]  
• Chin, K. M., Rubin, L. J. (2008). Pulmonary arterial hypertension.. J Am Coll Cardiol 51: 1527-1538 [Abstract] [Full Text]  
• National Pulmonary Hypertension Centres of the UK, (2008). Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 94: i1-i41 [Full Text]  
• National Pulmonary Hypertension Centres of the UK, (2008). Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 63: ii1-ii41 [Full Text]  
• El-Bizri, N., Wang, L., Merklinger, S. L., Guignabert, C., Desai, T., Urashima, T., Sheikh, A. Y., Knutsen, R. H., Mecham, R. P., Mishina, Y., Rabinovitch, M. (2008). Smooth Muscle Protein 22{alpha}-Mediated Patchy Deletion of Bmpr1a Impairs Cardiac Contractility but Protects Against Pulmonary Vascular Remodeling. Circ. Res. 102: 380-388 [Abstract] [Full Text]  
• Weir, E. K., Obreztchikova, M., Hong, Z. (2008). Fenfluramine: riddle or Rosetta stone?. Eur Respir J 31: 232-235 [Full Text]  
• Souza, R., Humbert, M., Sztrymf, B., Jais, X., Yaici, A., Le Pavec, J., Parent, F., Herve, P., Soubrier, F., Sitbon, O., Simonneau, G. (2008). Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 31: 343-348 [Abstract] [Full Text]  
• Zolkowska, D., Baumann, M. H., Rothman, R. B. (2008). Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels. J. Pharmacol. Exp. Ther. 324: 791-797 [Abstract] [Full Text]  
• Chapman, M. E., Taylor, R. L., Wideman, R F. Jr. (2008). Analysis of Plasma Serotonin Levels and Hemodynamic Responses Following Chronic Serotonin Infusion in Broilers Challenged with Bacterial Lipopolysaccharide and Microparticles. Poult. Sci. 87: 116-124 [Abstract] [Full Text]  
• Izikki, M., Hanoun, N., Marcos, E., Savale, L., Barlier-Mur, A. M., Saurini, F., Eddahibi, S., Hamon, M., Adnot, S. (2007). Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L1045-L1052 [Abstract] [Full Text]  
• Peacock, A. J., Murphy, N. F., McMurray, J. J. V., Caballero, L., Stewart, S. (2007). An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30: 104-109 [Abstract] [Full Text]  
• Klinger, J. R. (2007). Pulmonary Arterial Hypertension: An Overview. SEMIN CARDIOTHORAC VASC ANESTH 11: 96-103 [Abstract]  
• Jain, S., Ventura, H., deBoisblanc, B. (2007). Pathophysiology of Pulmonary Arterial Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 11: 104-109 [Abstract]  
• Edelman, J. D. (2007). Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 11: 110-118 [Abstract]  
• Wideman, R. F., Chapman, M. E., Hamal, K. R., Bowen, O. T., Lorenzoni, A. G., Erf, G. F., Anthony, N. B. (2007). An Inadequate Pulmonary Vascular Capacity and Susceptibility to Pulmonary Arterial Hypertension in Broilers. Poult. Sci. 86: 984-998 [Abstract] [Full Text]  
• Ni, W., Fink, G. D., Watts, S. W. (2007). The 5-Hydroxytryptamine2A Receptor Is Involved in (+)-Norfenfluramine-Induced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-Salt Hypertension. J. Pharmacol. Exp. Ther. 321: 485-491 [Abstract] [Full Text]  
• Remillard, C. V., Tigno, D. D., Platoshyn, O., Burg, E. D., Brevnova, E. E., Conger, D., Nicholson, A., Rana, B. K., Channick, R. N., Rubin, L. J., O'Connor, D. T., Yuan, J. X.-J. (2007). Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am. J. Physiol. Cell Physiol. 292: C1837-C1853 [Abstract] [Full Text]  
• Chin, K. M., Channick, R. N., Rubin, L. J. (2006). Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?. Chest 130: 1657-1663 [Abstract] [Full Text]  
• Chapman, M. E., Wideman, R. F. Jr. (2006). Evaluation of the Serotonin Receptor Blocker Methiothepin in Broilers Injected Intravenously with Lipopolysaccharide and Microparticles. Poult. Sci. 85: 2222-2230 [Abstract] [Full Text]  
• Morrell, N. W. (2006). Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling?. Proc Am Thorac Soc 3: 680-686 [Abstract] [Full Text]  
• Fantozzi, I., Platoshyn, O., Wong, A. H., Zhang, S., Remillard, C. V., Furtado, M. R., Petrauskene, O. V., Yuan, J. X.-J. (2006). Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L993-L1004 [Abstract] [Full Text]  
• Cohen, H. (2006). How to write a patient case report.. Am J Health Syst Pharm 63: 1888-1892 [Abstract] [Full Text]  
• McLaughlin, V. V., McGoon, M. D. (2006). Pulmonary Arterial Hypertension. Circulation 114: 1417-1431 [Full Text]  
• Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B. (2006). ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: e1-e148 [Full Text]  
• de Caestecker, M. (2006). Serotonin Signaling in Pulmonary Hypertension. Circ. Res. 98: 1229-1231 [Full Text]  
• Avorn, J. (2006). Evaluating Drug Effects in the Post-Vioxx World: There Must Be a Better Way. Circulation 113: 2173-2176 [Full Text]  
• Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., Eckel, R. H. (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss.. Arterioscler. Thromb. Vasc. Bio. 26: 968-976 [Abstract] [Full Text]  
• Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., Dromer, C., Pison, C., Reynaud-Gaubert, M., Haloun, A., Laurent, M., Hachulla, E., Simonneau, G. (2006). Pulmonary Arterial Hypertension in France: Results from a National Registry. Am. J. Respir. Crit. Care Med. 173: 1023-1030 [Abstract] [Full Text]  
• Eddahibi, S., Guignabert, C., Barlier-Mur, A.-M., Dewachter, L., Fadel, E., Dartevelle, P., Humbert, M., Simonneau, G., Hanoun, N., Saurini, F., Hamon, M., Adnot, S. (2006). Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension: Critical Role for Serotonin-Induced Smooth Muscle Hyperplasia. Circulation 113: 1857-1864 [Abstract] [Full Text]  
• Varghese, A., Hong, Z., Weir, E. K. (2006). Serotonin-Induced Inhibition of KV Current: A Supporting Role in Pulmonary Vasoconstriction?. Circ. Res. 98: 860-862 [Full Text]  
• Cogolludo, A., Moreno, L., Lodi, F., Frazziano, G., Cobeno, L., Tamargo, J., Perez-Vizcaino, F. (2006). Serotonin Inhibits Voltage-Gated K+ Currents in Pulmonary Artery Smooth Muscle Cells: Role of 5-HT2A Receptors, Caveolin-1, and KV1.5 Channel Internalization. Circ. Res. 98: 931-938 [Abstract] [Full Text]  
• Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., Eckel, R. H. (2006). Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113: 898-918 [Abstract] [Full Text]  
• Ray, W. A., Stein, C. M. (2006). Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board. NEJM 354: 194-201 [Full Text]  
• Lynch, M. J., Burns, R. G., Holcomb, J. E. (2005). Food for Thought: An Investigation of Food and Drug Administration Reporting Practices, 1995-1999. Criminal Justice Review 30: 293-311 [Abstract]  
• Marcos, E., Fadel, E., Sanchez, O., Humbert, M., Dartevelle, P., Simonneau, G., Hamon, M., Adnot, S., Eddahibi, S. (2005). Serotonin Transporter and Receptors in Various Forms of Human Pulmonary Hypertension. Chest 128: 552S-553S [Full Text]  
• Marcos, E., Fadel, E., Sanchez, O., Humbert, M., Dartevelle, P., Simonneau, G., Hamon, M., Adnot, S., Eddahibi, S. (2005). Serotonin Transporter and Receptors in Various Forms of Human Pulmonary Hypertension. Chest 128: 552S-553S [Full Text]  
• Grunig, E., Dehnert, C., Mereles, D., Koehler, R., Olschewski, H., Bartsch, P., Janssen, B. (2005). Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension. Chest 128: 630S-633S [Full Text]  
• Grunig, E., Dehnert, C., Mereles, D., Koehler, R., Olschewski, H., Bartsch, P., Janssen, B. (2005). Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension. Chest 128: 630S-633S [Full Text]  
• Weir, E. K., Lopez-Barneo, J., Buckler, K. J., Archer, S. L. (2005). Acute Oxygen-Sensing Mechanisms.. NEJM 353: 2042-2055 [Full Text]  
• Hong, Z., Smith, A. J., Archer, S. L., Wu, X.-C., Nelson, D. P., Peterson, D., Johnson, G., Weir, E. K. (2005). Pergolide Is an Inhibitor of Voltage-Gated Potassium Channels, Including Kv1.5, and Causes Pulmonary Vasoconstriction. Circulation 112: 1494-1499 [Abstract] [Full Text]  
• Rubin, L. J., Badesch, D. B. (2005). Evaluation and Management of the Patient with Pulmonary Arterial Hypertension. ANN INTERN MED 143: 282-292 [Abstract] [Full Text]  
• Lawrie, A., Spiekerkoetter, E., Martinez, E. C., Ambartsumian, N., Sheward, W. J., MacLean, M. R., Harmar, A. J., Schmidt, A.-M., Lukanidin, E., Rabinovitch, M. (2005). Interdependent Serotonin Transporter and Receptor Pathways Regulate S100A4/Mts1, a Gene Associated With Pulmonary Vascular Disease. Circ. Res. 97: 227-235 [Abstract] [Full Text]  
• Chaouat, A., Bugnet, A.-S., Kadaoui, N., Schott, R., Enache, I., Ducolone, A., Ehrhart, M., Kessler, R., Weitzenblum, E. (2005). Severe Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 172: 189-194 [Abstract] [Full Text]  
• Baker, S. E, Hockman, R. H. (2005). Inhaled Iloprost in Pulmonary Arterial Hypertension. The Annals of Pharmacotherapy 39: 1265-1274 [Abstract] [Full Text]  
• Task Force members, , Galie, N., Torbicki, A., Barst, R., Dartevelle, P., Haworth, S., Higenbottam, T., Olschewski, H., Peacock, A., Pietra, G., Rubin, L. J., Simonneau, G. (2004). Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25: 2243-2278 [Full Text]  
• Rezaie-Majd, S., Murar, J., Nelson, D. P., Kelly, R. F., Hong, Z., Lang, I. M., Varghese, A., Weir, E. K. (2004). Increased release of serotonin from rat ileum due to dexfenfluramine. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287: R1209-R1213 [Abstract] [Full Text]  
• Martinez-Taboada, V. M., Rodriguez-Valverde, V., Gonzalez-Vilchez, F., Armijo, J. A. (2004). Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. Rheumatology (Oxford) 43: 1451-1452 [Full Text]  
• Farber, H. W., Loscalzo, J. (2004). Pulmonary Arterial Hypertension. NEJM 351: 1655-1665 [Full Text]  
• Velez-Roa, S., Ciarka, A., Najem, B., Vachiery, J.-L., Naeije, R., van de Borne, P. (2004). Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension. Circulation 110: 1308-1312 [Abstract] [Full Text]  
• Naeije, R., Eddahibi, S. (2004). Serotonin in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 170: 209-210 [Full Text]  
• Barst, R J, Abenhaim, L (2004). Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 90: e42-e42 [Abstract] [Full Text]  
• McGoon, M., Gutterman, D., Steen, V., Barst, R., McCrory, D. C., Fortin, T. A., Loyd, J. E. (2004). Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 126: 14S-34S [Abstract] [Full Text]  
• Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., McLaughlin, V. V. (2004). Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 126: 35S-62S [Abstract] [Full Text]  
• Newman, J. H., Trembath, R. C., Morse, J. A., Grunig, E., Loyd, J. E., Adnot, S., Coccolo, F., Ventura, C., Phillips, J. A. III, Knowles, J. A., Janssen, B., Eickelberg, O., Eddahibi, S., Herve, P., Nichols, W. C., Elliott, G. (2004). Genetic basis of pulmonary arterial hypertension: Current understanding and future directions. J Am Coll Cardiol 43: 33S-39S [Abstract] [Full Text]  
• Weir, E. K., Hong, Z., Varghese, A. (2004). The Serotonin Transporter: A Vehicle to Elucidate Pulmonary Hypertension?. Circ. Res. 94: 1152-1154 [Full Text]  
• Marcos, E., Fadel, E., Sanchez, O., Humbert, M., Dartevelle, P., Simonneau, G., Hamon, M., Adnot, S., Eddahibi, S. (2004). Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension. Circ. Res. 94: 1263-1270 [Abstract] [Full Text]  
• Di Sacco, G. (2004). Amfepramone does not cause primary pulmonary hypertension. Eur Respir J 23: 790-790 [Full Text]  
• Abramowicz, M., Delcroix, M. (2004). From the Authors. Eur Respir J 23: 790-791 [Full Text]  
• Younger, J. R., Lui, C. Y. (2004). Paradoxical Effect of Prostacyclin Infusion in a Patient with Primary Pulmonary Hypertension: A Case Report. ANGIOLOGY 55: 341-344 [Abstract]  
• Chaouat, A, Coulet, F, Favre, C, Simonneau, G, Weitzenblum, E, Soubrier, F, Humbert, M (2004). Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 59: 446-448 [Abstract] [Full Text]  
• Murphy, D. L., Lerner, A., Rudnick, G., Lesch, K.-P. (2004). Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics. Mol. Interv. 4: 109-123 [Abstract] [Full Text]  
• Hong, Z., Olschewski, A., Reeve, H. L., Nelson, D. P., Hong, F., Weir, E. K. (2004). Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am. J. Physiol. Lung Cell. Mol. Physiol. 286: L531-L538 [Abstract] [Full Text]  
• Eickelberg, O., Yeager, M. E, Grimminger, F. (2003). The tantalizing triplet of pulmonary hypertension--BMP receptors, serotonin receptors, and angiopoietins. Cardiovasc Res 60: 465-467 [Full Text]  
• Blanpain, C., Le Poul, E., Parma, J., Knoop, C., Detheux, M., Parmentier, M., Vassart, G., Abramowicz, M. J (2003). Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 60: 518-528 [Abstract] [Full Text]  
• Eddahibi, S., Chaouat, A., Morrell, N., Fadel, E., Fuhrman, C., Bugnet, A.-S., Dartevelle, P., Housset, B., Hamon, M., Weitzenblum, E., Adnot, S. (2003). Polymorphism of the Serotonin Transporter Gene and Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease. Circulation 108: 1839-1844 [Abstract] [Full Text]  
• Cool, C. D., Rai, P. R., Yeager, M. E., Hernandez-Saavedra, D., Serls, A. E., Bull, T. M., Geraci, M. W., Brown, K. K., Routes, J. M., Tuder, R. M., Voelkel, N. F. (2003). Expression of Human Herpesvirus 8 in Primary Pulmonary Hypertension. NEJM 349: 1113-1122 [Abstract] [Full Text]  
• Rondelet, B., Van Beneden, R., Kerbaul, F., Motte, S., Fesler, P., McEntee, K., Brimioulle, S., Ketelslegers, J-M., Naeije, R. (2003). Expression of the serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J 22: 408-412 [Abstract] [Full Text]  
• Abramowicz, M.J., Van Haecke, P., Demedts, M., Delcroix, M. (2003). Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 22: 560-562 [Abstract] [Full Text]  
• Marcos, E., Adnot, S., Pham, M. H., Nosjean, A., Raffestin, B., Hamon, M., Eddahibi, S. (2003). Serotonin Transporter Inhibitors Protect against Hypoxic Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. 168: 487-493 [Abstract] [Full Text]  
• Weigle, D. S. (2003). Pharmacological Therapy of Obesity: Past, Present, and Future. J. Clin. Endocrinol. Metab. 88: 2462-2469 [Full Text]  
• Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., Roth, B. L. (2003). 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. Mol. Pharmacol. 63: 1223-1229 [Abstract] [Full Text]  
• Stafford, R. S., Radley, D. C. (2003). National Trends in Antiobesity Medication Use. Arch Intern Med 163: 1046-1050 [Abstract] [Full Text]  
• Suzuki, Y. J., Day, R. M., Tan, C. C., Sandven, T. H., Liang, Q., Molkentin, J. D., Fanburg, B. L. (2003). Activation of GATA-4 by Serotonin in Pulmonary Artery Smooth Muscle Cells. J. Biol. Chem. 278: 17525-17531 [Abstract] [Full Text]  
• Morse, J H (2003). Genetic studies of pulmonary arterial hypertension. Lupus 12: 209-212 [Abstract]